KPIs & Operating Metrics(New)
Growth Metrics

Astrazeneca (AZN) Finished Goods (2016 - 2024)

Historic Finished Goods for Astrazeneca (AZN) over the last 10 years, with Q4 2024 value amounting to $1.5 billion.

  • Astrazeneca's Finished Goods fell 325.26% to $1.5 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $1.5 billion, marking a year-over-year decrease of 325.26%. This contributed to the annual value of $1.5 billion for FY2024, which is 325.26% down from last year.
  • Per Astrazeneca's latest filing, its Finished Goods stood at $1.5 billion for Q4 2024, which was down 325.26% from $1.6 billion recorded in Q4 2023.
  • In the past 5 years, Astrazeneca's Finished Goods ranged from a high of $2.0 billion in Q4 2021 and a low of $1.4 billion during Q4 2022
  • Over the past 5 years, Astrazeneca's median Finished Goods value was $1.5 billion (recorded in 2024), while the average stood at $1.6 billion.
  • In the last 5 years, Astrazeneca's Finished Goods soared by 4060.1% in 2021 and then tumbled by 2977.14% in 2022.
  • Over the past 5 years, Astrazeneca's Finished Goods (Quarter) stood at $1.4 billion in 2020, then skyrocketed by 40.6% to $2.0 billion in 2021, then fell by 29.77% to $1.4 billion in 2022, then grew by 10.97% to $1.6 billion in 2023, then decreased by 3.25% to $1.5 billion in 2024.
  • Its Finished Goods was $1.5 billion in Q4 2024, compared to $1.6 billion in Q4 2023 and $1.4 billion in Q4 2022.